Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in KRAS G12R-mutated advanced pancreatic cancer
NCT03040986Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in pancreatic cancer (PC), sponsored by National Cancer Institute. Started Jul 2017; status: completed.
02
Drugs
selumetinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03040986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03040986.